IRLAB publishes interim report for the period January – March 2026

Gothenburg, Sweden, May 6, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the interim report for the period January-March 2026, has been published.

IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing

IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast